Unlocking the Power of NK Cells — A Detailed Guide to Cultivation Methods and Key Cytokine Functions

Date : 2026-04-21

As Natural Killer (NK) cell therapy establishes its significance in the treatment of both haematological malignancies and solid tumours, the stable, efficient, and scalable production of clinical-grade NK cells has emerged as a primary technical hurdle. Unlike T-cell expansion, the in vitro cultivation of NK cells requires a sophisticated integration of activating and inhibitory signals. This article provides a rigorous examination of NK cell bioprocessing, evaluating the transition from traditional feeder-dependent co-cultures to contemporary feeder-free, chemically defined systems, while elucidating the fundamental roles of cytokines in directing lineage specification and effector function.

I. The "Three Kingdoms" of NK Cell Sources

The therapeutic efficacy and manufacturing scalability of NK cell products are fundamentally dictated by their source material.

Peripheral Blood NK Cells (PB-NKs): Isolated from healthy adult donors, PB-NKs represent the traditional benchmark. These cells possess a mature phenotype and potent immediate cytotoxicity. However, their clinical application is constrained by low frequency (5–15% of lymphocytes), significant inter-donor variability, and inherent resistance to viral transduction and genetic modification.
Cord Blood NK Cells (CB-NKs): Derived either directly from umbilical cord blood or differentiated from CD34+ haematopoietic stem and progenitor cells (HSPCs). CB-NKs offer a more primitive phenotype with superior proliferative capacity compared to PB-NKs. Their relative abundance and lower risk of Graft-versus-Host Disease (GvHD) make them optimal candidates for "off-the-shelf" allogeneic therapies.
Stem Cell-Derived NK Cells (iPSC-NKs): NK cells differentiated from induced pluripotent stem cells (iPSCs) represent the frontier of cellular engineering. iPSCs provide an inexhaustible starting material amenable to precise genetic editing (e.g., CAR insertion) at the single-cell level, facilitating the production of highly homogenous, standardised cellular batches.

II. Traditional Method: Feeder Cell-Dependent Expansion

For several decades, the expansion of NK cells to clinically relevant numbers has relied upon co-culture with feeder cells. These cells—typically gamma-irradiated to prevent their own proliferation—act as surrogates for the immune microenvironment.
The most prevalent model employs genetically modified K562 cells (a chronic myeloid leukaemia line). By engineering K562 cells to express membrane-bound ligands such as 4-1BB ligand (4-1BBL) and cytokines like IL-15 or IL-21 (mbIL-15/mbIL-21), researchers have achieved massive expansion ratios. Notably, K562 cells expressing mbIL-21 have been shown to drive over 2000-fold expansion within 21 days (Motallebnejad et al., 2025).

Despite their efficacy, feeder-dependent systems introduce significant challenges:

Regulatory Risk: The potential for residual tumour-derived feeder cells in the final product necessitates exhaustive safety validation to mitigate tumorigenicity risks.
Quality Control Difficulty: Maintaining consistency across feeder cell batches and their metabolic activity levels complicates Good Manufacturing Practice (GMP) compliance.
Process Complexity: The requirement for cell-to-cell contact complicates the transition to closed, automated bioreactor systems.
Therefore, developing feeder-free, chemically defined, GMP-compliant culture systems that do not depend on feeder cells has become a shared goal for both industry and regulatory bodies.

III. Feeder-Free Systems: From "Dependence" to "Independence"

The current industrial trajectory favours the development of feeder-free systems that utilise exogenous factors to replicate essential activation signals.

1. Optimised Cytokine Combinations

Cytokines are the "chemical language" regulating NK cell fate. Research shows that some cytokines are "essentials" — sufficient to induce proliferation on their own — while others are "synergists" that require combination with essentials for maximum efficacy.

Foundational Factors: IL-2 and IL-15 serve as the requisite pillars for basal survival and proliferation (Ma et al., 2024; Sun et al., 2003).
Synergistic Drivers: IL-21 acts as a potent orchestrator of expansion (Spolski & Leonard, 2008). While insufficient as a monotherapy, transient exposure to IL-21 in the early culture phase, in conjunction with IL-15, can enhance expansion yields by up to 10-fold by priming the proliferative machinery (Nutt et al., 2004).
Effector Enhancers: IL-12 and IL-18 are frequently utilised in the terminal stages of culture to polarise cells towards a highly active phenotype, characterised by increased IFN-γ production and enhanced cytolytic receptor expression (Ohno et al., 2025).

2. Antibody Stimulation Methods

Borrowing from T-cell manufacturing protocols, antibody-mediated activation provides a controlled alternative to feeder cells.

Paracrine Activation via OKT-3: Anti-CD3 (OKT-3) antibodies, while targeting T cells, can indirectly drive NK expansion within PBMC populations by triggering T-cell-derived cytokine secretion (Satwani et al., 2011).
Direct Receptor Ligation: Selective activation via antibodies targeting NKp46, CD2, and CD16 mimics the physiological "missing self" or ADCC (antibody-dependent cellular cytotoxicity) signals, allowing for the expansion of high-purity NK cell populations (Lim et al., 2012).

3. Next-Generation Technologies: Nanoparticles and 3D Culture

To further achieve large-scale, standardised production, nanotechnology and biomaterials are deeply integrating with cell culture processes.

Nanoparticles: Can mimic the contact signals provided by feeder cells. For instance, signals that activate NK cells (e.g., anti-NKG2D antibodies, IL-15 fusion proteins) are conjugated to magnetic nanobeads or biodegradable nanoparticles, providing artificial "antigen-presenting" stimulation to NK cells. This strategy not only efficiently expands NK cells but also avoids biological contamination, and nanoparticles are easily removed by washing.
Biomaterials and 3D Culture: Mimic the 3D microenvironment of bone marrow or lymph nodes, providing more biomimetic physical support and cell-cell interactions for iNK cell differentiation or NK cell proliferation.

IV. Detailed Functions of Key Cytokines

Throughout the entire lifecycle of NK cells, different cytokines play distinct roles. The following table delineates the specific roles and applications of key cytokines within the NK cell lifecycle.

Cytokine	Main Source	Core Function	Typical Application in Culture Protocols
IL-2	Activated T cells	Promotes T and NK cell proliferation, activation, enhances cytotoxicity (Ma et al., 2024).	Essential component of basal expansion media; maintains NK cell survival.
IL-7	Stromal cells	Promotes homeostatic proliferation and survival of lymphocytes (including NK precursors).	Used in early stages of NK cell differentiation from HSPCs or iPSCs.
IL-15	Monocytes, Dendritic cells	Most critical survival and proliferation factor for NK cells. Promotes NK cell development, maintains in vivo homeostasis, enhances killing function (Sun et al., 2003).	Core cytokines throughout the expansion process, whether for primary NK expansion or iPSC/HSPC differentiation.
IL-18	Macrophages, Dendritic cells	Enhances NK cell maturation, IFN-γ secretion, and cytotoxicity; often synergizes with IL-12 (Ohno et al., 2025).	Typically added in later culture stages or during activation to enhance functional maturity of NK cells.
IL-21	Activated CD4+ T cells, NKT cells	Regulates NK cell homeostasis and function. Short-term treatment promotes proliferation and killing activity; long-term treatment induces terminal differentiation and limits over-expansion (Spolski & Leonard, 2008).	Often used transiently early in culture (primary expansion) or at specific stages (e.g., late iPSC differentiation) to optimize final product effector function.
FLT3L	Various cells	Acts on hematopoietic stem/progenitor cells, promoting differentiation towards dendritic cell and NK cell lineages (Satwani et al., 2011).	Essential at the initial stage of inducing differentiation from CD34+ HSPCs or iPSCs into NK cells.
SCF	Stromal cells	Stem cell factor supports survival, proliferation, and maintenance of undifferentiated state in hematopoietic stem/progenitor cells (Colucci et al., 2000).	Also used in early stages of NK cell differentiation, synergising with FLT3L.
TPO	Liver, Kidneys	Thrombopoietin, primarily stimulates megakaryocyte proliferation and differentiation, also expands HSPCs (Mesquitta et al., 2019).	Often used in combination with SCF and FLT3L during CD34+ HSPC expansion phase.

V. Case Study: Standardised Production of NK Cells from iPSCs

Taking the highly regarded iPSC-NK differentiation as an example, let's examine a typical feeder-free culture process (Zhu & Kaufman, 2019). The core advantages of this protocol are:

Complete elimination of feeder and stromal cells, avoiding animal-derived contamination
Two-stage liquid culture, providing a clear process amenable to scale-up.

Stage 1: Days 0–11 – Hematopoietic Differentiation (Embryoid Body Method)

Time	Operation & Factor Addition	Objective	Cell Product
Day 0	Dissociate feeder-free cultured iPSCs into single cells; seed in ultra-low attachment plates; add ROCK inhibitor (e.g., Y-27632) in serum-free medium (e.g., STEMdiff™ APEL2™) to form embryoid bodies (EBs).	Initiate iPSC differentiation into three germ layers, lay foundation for hematopoietic differentiation; ROCK inhibitor improves single-cell survival.	Embryoid bodies (EBs) containing undifferentiated iPSC aggregates.
Day 0-11	Sequentially or combinatorially add BMP4, VEGF, SCF, FLT3L, IL-3, etc., to the medium.	BMP4 and VEGF induce mesodermal and endothelial-hematopoietic lineage specification; SCF, FLT3L, IL-3 promote generation and expansion of hematopoietic stem/progenitor cells.	Generation of CD34+CD45+ hematopoietic stem/progenitor cells within EBs.
Day 11 Endpoint:	Collect EBs, obtaining a population enriched in CD34+ hematopoietic precursors as the starting cells for the next stage of NK-directed differentiation.

Stage 2: Day 11 – Week 4 – NK-directed Differentiation

Time	Operation & Factor Addition	Objective	Cell Product
Day 11 - Week 4	Transfer hematopoietic precursor-containing EBs or CD34+ cells isolated from EBs into a feeder-free culture system using NK cell differentiation medium (containing SCF, FLT3L, IL-3, IL-15, IL-7).	Generation and expansion of CD56+CD3- NK cells, culminating in mature, functional NK cells.	CD56+CD3- NK cells gradually appear and expand.
Day 11 - Week 4	SCF & FLT3L support precursor survival & proliferation; IL-3 (transient) promotes myeloid potential; IL-7 supports lymphocyte lineage survival; IL-15 is the most critical factor driving NK cell lineage specification, survival, and proliferation.		CD56+CD3- NK cells gradually appear and expand.
Week 4 Endpoint	Flow cytometry typically shows >80% CD56+CD3- cells. These cells express activating receptors like NKG2D and NKp46 and possess cytotoxic function.

Stage 3: Week 4 – Week 8 – Clinical-scale NK Expansion

While Zhu et al. (2019) suggest that NK cells obtained at week 4 can be co-cultured with irradiated mbIL-21-K562 cells for large-scale expansion to reach clinically required cell numbers, we recommend a feeder-free, chemically defined expansion protocol (Nakazawa et al., 2023) from a clinical-grade preparation safety and quality control perspective. This protocol uses antibody coating (anti-NKp46 and anti-CD16) to provide activation signals, completely eliminating reliance on feeder cells, avoiding tumorigenicity risks and batch-to-batch variation, and better aligning with current industrialisation standards for cell therapy.
It should be noted that this expansion step is an extension and scale-up of the production process, not an integral part of the basic differentiation protocol, and can thus be seamlessly connected with the iPSC-NK differentiation process of Zhu & Kaufman (2019). Although Nakazawa et al.'s original protocol was based on cord blood-derived NK cells, its core feeder-free, antibody-coating platform is equally applicable to the subsequent expansion of iPSC-NKs, representing the direction of next-generation "off-the-shelf" cell products.

Time	Operation & Factor Addition	Objective	Cell Product
Day 0	Seed T-cell-depleted NK cells (obtained from iPSC differentiation or cord blood) into culture vessels pre-coated with anti-NKp46 and anti-CD16 antibodies. Add recombinant human IL-18 and high-dose IL-2 to the medium.	Antibody Coating: Anti-NKp46 and anti-CD16 agonise activating receptors on NK cells, providing potent activation signals mimicking target cell contact. Cytokines: IL-2 is a core factor for NK cell survival and proliferation; IL-18 synergistically enhances IFN-γ secretion and cytotoxic function.	Starting NK cells (CD3-CD56+).
Day 0-7	Maintain antibody coating conditions; continuously add IL-18 and IL-2 to the medium; half-medium change every 2-3 days.	Continuously provide activation and survival signals, driving NK cells into rapid proliferation cycles.	After 7 days of expansion, CD3-CD56+ NK cell purity can reach >80%.
Days 7-14	Transfer cells to new antibody-coated plates or maintain original conditions; continuously add IL-18 and IL-2 to the medium.	Prevent contact inhibition; maintain sustained stimulation by activation signals.	After 14 days of expansion, NK cell purity can reach >98%, with high expression of activating receptors (NKG2D, DNAM-1, NKp30, NKp44, etc.).
Days 14-21	Maintain same culture conditions; passage as needed based on cell density.	Continuously expand to clinically required cell numbers (typically 10⁷–10⁹/kg per patient dose).	After 21 days of expansion, NK cell purity can reach >99%, yielding large quantities of highly pure, highly cytotoxic mature NK cells.
Key Result:	This protocol achieves >99% pure CD3-CD56+ NK cells over a 21-day expansion cycle. The cells highly express activating receptors like LFA-1, NKG2D, DNAM-1, NKp30, and NKp46, demonstrating significant cytotoxicity against the glioblastoma cell line T98G.

Conclusion

Moving from the "manual workshop" era dependent on feeder cells to the "industrial mass production" era characterised by feeder-free, chemically defined, closed, and automated systems, the in vitro manufacturing process for NK cells is undergoing a profound transformation. Precise understanding and application of cytokine networks, coupled with the cross-integration of novel biomaterials, are continuously lowering the cost and improving the accessibility of NK cell therapies. Mastering these core cultivation technologies will be key to standing out in the fiercely competitive future cell therapy market.

References

Boissel, L., Tuncer, H. H., Betancur, M., Wolfberg, A., & Klingemann, H. (2008). Umbilical cord mesenchymal stem cells increase expansion of cord blood natural killer cells. Biology of Blood and Marrow Transplantation, *14*(9), 1031-1038.
Colucci, F., Di Santo, J. P., & Leibson, P. J. (2000). The receptor tyrosine kinase c-kit provides a critical signal for survival, expansion, and maturation of mouse natural killer cells. Blood, *95*(3), 984-991.
Lim, K. H., Park, J. Y., Kim, J. H., & Lee, W. W. (2012). Generation of CD2(+)CD8(+) NK cells from c-kit(+) bone marrow cells in porcine. Korean Journal of Physiology & Pharmacology, *16*(3), 197-203.
Ma, L., Zhang, J., Liu, Y., & Wang, X. (2024). A precision engineered interleukin-2 for bolstering CD8+ T- and NK-cell activity without eosinophilia and vascular leak syndrome in nonhuman primates. Cancer Research Communications. Advance online publication.
Mesquitta, W. T., Wandsnider, M., Kang, H. J., Thomson, J. A., & Slukvin, I. I. (2019). UM171 expands distinct types of myeloid and NK progenitors from human pluripotent stem cells. Scientific Reports, *9*(1), Article 6622.
Motallebnejad, P., Zhang, X., & Chen, Y. (2025). Integrated ATAC-seq and RNA-seq analysis identifies key regulatory elements in NK cells activated with feeder cells and IL-2. Bioengineering & Translational Medicine, *10*(3), e10747.
Nakazawa, T., Maeoka, R., Morimoto, T., Matsuda, R., Nakamura, M., Nishimura, F., ... & Tsujimura, T. (2023). An efficient feeder-free and chemically-defined expansion strategy for highly purified natural killer cells derived from human cord blood. Regenerative Therapy, 24, 32-42.
Nutt, S. L., Brady, J., Hayakawa, Y., & Smyth, M. J. (2004). Interleukin 21: A key player in lymphocyte maturation. Critical Reviews in Immunology, *24*(4), 239-250.
Ohno, Y., Kitamura, H., & Nishimura, T. (2025). IL-18-primed NK cells recruit dendritic cells and potentiate tumor therapy mediated by PD-1 blockade. Frontiers in Oncology, *15*, Article 1533808.
Satwani, P., van de Ven, C., Ayello, J., Cairo, D., Simpson, L. L., Baxi, L., & Cairo, M. S. (2011). Interleukin (IL)-15 in combination with IL-2, fms-like tyrosine kinase-3 ligand and anti-CD3 significantly enhances umbilical cord blood natural killer (NK) cell and NK-cell subset expansion and NK function. Cytotherapy, *13*(6), 730-738.
Spolski, R., & Leonard, W. J. (2008). Interleukin-21: Basic biology and implications for cancer and autoimmunity. Annual Review of Immunology, *26*, 57-79.
Sun, R., Fan, J., Wei, H., Zhang, C., & Tian, Z. (2003). Use of interleukin-15 for preparation of adherent NK cells from human peripheral blood: Comparison with interleukin-2. Journal of Immunological Methods, *279*(1-2), 79-90.
Zhu, H., & Kaufman, D. S. (2019). An improved method to produce clinical-scale natural killer cells from human pluripotent stem cells. In Vitro Differentiation of T-Cells: Methods and Protocols (pp. 107-119). New York, NY: Springer New York.